. JNJ-28312141 | CAS#885692-52-4 | CSF1R inhibitor | MedKoo Biosciences

MedKoo Biosciences

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us





Back to products


 Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries


Other drug agents

Drug intermediates

Bio-reagents and biochemicals









MedKoo product information:




Description of  JNJ-28312141: JNJ-28312141 is an orally active CSF1R inhibitor (Colony-stimulating factor-1 receptor, CRF1R) and also a FLT3 inhibitor. CSF1R  is expressed by many tumors and is a growth factor for macrophages and mediates osteoclast differentiation.  JNJ-28312141 represents a new agent with potential therapeutic activity in acute myeloid leukemia and in settings where CSF-1-dependent macrophages and osteoclasts contribute to tumor growth and skeletal events. (last updated: 8/25/2015).


Current developer:  Johnson & Johnson.


MedKoo Cat#: 406201

Name: JNJ-28312141

CAS#: 885692-52-4

Synonym:  JNJ-28312141; JNJ28312141; JNJ 28312141.

IUPAC/Chemical name: 


Chemical structure

Theoretical analysis

JNJ-28312141 structure

MedKoo Cat#:  406201
Name:  JNJ-28312141
CAS#: 885692-52-4

Chemical Formula: C26H32N6O2
Exact Mass: 460.25867
Molecular Weight: 460.57
Elemental Analysis: C, 67.80; H, 7.00; N, 18.25; O, 6.9


Availability and price:

JNJ-28312141, purity > 98%, is available through custom synthesis. Minimum 1 gram order is requested. Current shipping out time is about 70 days after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee:  $30.00 (USA); from $45.00 (Canada); from $70.00 (international).

10mg / not available

25mg / not available

50mg / not available

100mg / not available

200mg / not available

500mg / not available

1.0g / Ask price

2.0g / Ask price

5.0g / Ask price

Please ask price and availability of other quantity.



Technical data


Solid powder


>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

View CoA: current batch, Lot#  (will be available for download when it's in stock)

QC data:

View QC data: current batch, Lot#  (will be available for download when it's in stock)

Safety Data Sheet (MSDS):

View Material Safety Data Sheet (MSDS)  (will be available for download when it's in stock)

Shipping condition:

Shipped under ambient temperature as non-hazardous chemical.  This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage condition:

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).


Soluble in DMSO, not in water

Shelf life:

>2 years if stored properly

Drug formulation:

This drug may be formulated in DMSO

Stock solution storage:

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Note: The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.


Protocols from literature

In vitro protocol:


In vivo protocol:


Review papers:



Information about this agent





1: Illig CR, Manthey CL, Wall MJ, Meegalla SK, Chen J, Wilson KJ, Ballentine SK,  Desjarlais RL, Schubert C, Crysler CS, Chen Y, Molloy CJ, Chaikin MA, Donatelli RR, Yurkow E, Zhou Z, Player MR, Tomczuk BE. Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]pheny l]-1H-imidazole-2-carboxamide (JNJ-28312141). J Med Chem. 2011 Nov24;54(22):7860-83. doi: 10.1021/jm200900q. Epub 2011 Oct 31. PubMed PMID: 22039836.

2: Manthey CL, Johnson DL, Illig CR, Tuman RW, Zhou Z, Baker JF, Chaikin MA, Donatelli RR, Franks CF, Zeng L, Crysler C, Chen Y, Yurkow EJ, Boczon L, Meegalla SK, Wilson KJ, Wall MJ, Chen J, Ballentine SK, Ott H, Baumann C, Lawrence D, Tomczuk BE, Molloy CJ. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther. 2009 Nov;8(11):3151-61. doi: 10.1158/1535-7163.MCT-09-0255. Epub 2009 Nov 3. PubMed PMID: 19887542.




Contact MedKoo:

Tel: 919-636-5577
Fax: 919-980-4831
Email: sales@medkoo.com


(Keyword; CAS#; MedKoo Cat#)








About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

MedKoo Biosciences. All Rights Reserved